← Browse by Condition
Medical Condition

lung adenocarcinoma

Total Trials
4
Recruiting Now
4
Trial Phases
Various

ClinicalMetric tracks all active clinical trials for lung adenocarcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — lung adenocarcinoma Clinical Trials

How many clinical trials are currently recruiting for lung adenocarcinoma?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for lung adenocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for lung adenocarcinoma?
lung adenocarcinoma research spans multiple clinical trial phases. Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a lung adenocarcinoma clinical trial?
Eligibility criteria for lung adenocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Shanghai Pulmonary Hospital, Shanghai, China 1 trial
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 1 trial
Fondazione del Piemonte per l'Oncologia 1 trial
University of Colorado, Denver 1 trial

Recruiting Clinical Trials

NCT05925764
Recruiting
WSI Based DL for Diagnosing the IASLC Grading System of Lung Adenocarcinoma
Enrollment
200 pts
Location
China
Sponsor
Shanghai Pulmonary Hospital, S...
View Trial →
NCT05537922
Recruiting
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Enrollment
2,200 pts
Location
United States, Greec...
Sponsor
Fondazione IRCCS Istituto Nazi...
View Trial →
NCT07479095
Recruiting
Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic-predominant Growth Lung Adenocarcinoma
Enrollment
30 pts
Location
Italy
Sponsor
Fondazione del Piemonte per l'...
View Trial →
NCT05517811
Recruiting
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
Enrollment
400 pts
Location
United States
Sponsor
University of Colorado, Denver
View Trial →

Related Conditions

whole slide image (1) iaslc grading system (1) artificial intelligence (1) non small cell lung cancer (1) lung cancer metastatic (1) lung cancer nonsmall cell (1) lepidic predominant lung adenocarcinoma (1) liver cancer (1) esophageal cancer (1) colorectal cancer (1) control (1) pancreas cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology